Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma
- Status
- RECRUITING
- Phase
- PHASE1
Clinical Trials Related to Irinotecan
Related studies linked through entity extraction aliases.
A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer
- Status
- RECRUITING
- Phase
- PHASE1
Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations
- Status
- RECRUITING
- Phase
- PHASE3
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1
A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
- Status
- RECRUITING
- Phase
- PHASE3
AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer
- Status
- RECRUITING
- Phase
- PHASE3
NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Hypofractionated Radiotherapy Plus Immunotherapy Versus Conventional Radiotherapy in Locally Recurrent Rectal Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Testing Ivonescimab in Combination With Chemotherapy in Advanced or Metastatic Gastric/Gastroesophageal Adenocarcinoma
- Status
- RECRUITING
- Phase
- PHASE2
Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Preoperative Chemoradiotherapy and Toripalimab in Locally Recurrent Rectal Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
- Status
- RECRUITING
- Phase
- PHASE3
ValproIc Acid to Potentiate Anti-EGFR Treatment Efficacy and Prevent/Revert Resistance in Colorectal Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1
Cetuximab, Irinotecan, Toripalimab in RAS/BRAF Wild-type Ultraselected Right-sided Colorectal Cancer Study
- Status
- RECRUITING
- Phase
- PHASE2
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2